Nivisnebart

N/A

Report date: 2025/12/29 10:50:38

Base Information

Drug NameNivisnebart
Drug Alias NameGSK-4527226AL-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgranulin modulators
TargetsProgranulin
Therapy Area/IndicationsNerve DegenerationAmyotrophic Lateral SclerosisFrontotemporal Dementia +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[15
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlector Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsNerve DegenerationAmyotrophic Lateral SclerosisFrontotemporal Dementia +[5
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A